Banti Christina N, Hadjikakou Sotiris K
Section of Inorganic and Analytical Chemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece.
Bio Protoc. 2019 Jul 20;9(14):e3311. doi: 10.21769/BioProtoc.3311.
The and genotoxicity of new metallodrugs either as Small Bioactive Molecules (SBAMs) or Conjugates of Metals with Drugs (CoMeDs) is evaluated by the micronucleus test and the assay, respectively. Fetal lung fibroblast cells (MRC-5), normal human corneal epithelial cells (HCEC) and immortalized human keratinocytes cells (HaCaT) were incubated with solutions of SBAMs or CoMeDs at their IC values for 48 h (the concentration of a compound which is required to inhibit the cells growth by 50% in relation to the non-treated cells). The micronucleus abundance percentage towards the corresponding one, of the non-treated cells indicates the genotoxicity of the formulations. The test comprises the exposing of the plant roots to an SBAMs or a CoMeDs solution for 48 h. The percentages of the mitotic index, the chromosome aberrations, the nuclear abnormalities and the presence of the micronucleus are calculated indicating the genotoxicity of the agent.
新型金属药物作为小生物活性分子（SBAMs）或金属与药物的缀合物（CoMeDs）的细胞毒性和基因毒性分别通过微核试验和彗星试验进行评估。将胎儿肺成纤维细胞（MRC-5）、正常人角膜上皮细胞（HCEC）和永生化人角质形成细胞（HaCaT）与SBAMs或CoMeDs溶液在其IC值下孵育48小时（相对于未处理细胞，抑制细胞生长50%所需的化合物浓度）。与未处理细胞相比，处理后细胞的微核丰度百分比表明制剂的细胞毒性。彗星试验包括将植物根尖暴露于SBAMs或CoMeDs溶液中48小时。计算有丝分裂指数、染色体畸变、核异常和微核存在的百分比，以表明该试剂的基因毒性。
